Skip to main content
. 2020 Jan 23;12(2):92. doi: 10.3390/pharmaceutics12020092

Table 1.

Antigens and diseases treated with RNA-transfected DCs.

RNA Used Malignancy/Disease Patients Vaccinated Phase DC Culturing Maturation Reference
Autologous tumor RNA (aT-RNA) Colorectal ca m 15 I Standard (including FCS) No [29]
Colon ca 1 0 Standard TNFα [30]
Renal cell ca m 10 I Standard No [31]
Pediatric brain tumors 7 I Standard No [32]
Pediatric neuroblastoma stage IV 8 I Standard No [33]
Renal cell ca m, ovarian ca 11 ns Standard MCMM [34]
Melanoma stage IV 6 I Standard (Clinimacs) TNFα + PGE2 [35]
Renal cell ca m 21 II Standard TNFα + PGE2 + IFNγ + CD40L-mRNA [36]
Melanoma stage IV 31 I/II Standard MCMM [37]
aTSC-RNA (tumor stem cells) Glioblastoma 7 I/II Standard (5 days) MCMM [38]
Allogeneic tumor RNA (3 human cancer cell lines) Prostate ca 19 I/II Standard MCMM [39]
MAGE-A1- MAGE-A3-, MAGE-C2-, MelanA-, tyrosinase-, and/or gp100-DC-Lamp mRNA Melanoma stage III and IV 30 I * Standard (6 days) TriMix or polyIC + CD40L-mRNA [40]
MAGE-A3-, MAGE-C2-, tyrosinase-, gp100-DC-Lamp mRNA Melanoma stage IIIC and IV 35 I * Standard (6 days) TriMix- mRNA [41]
Melanoma stage IIIC and IV 15 IB Standard (6 days) TriMix-mRNA [42]
Melanoma stage IIIC and IV 39 II Standard (6 days) TriMix-mRNA [43]
gp100 or tyrosinase mRNA Melanoma m stage III 11 I/II Standard MCM + TNFα + PGE2 [44]
gp100 and tyrosinase mRNA Melanoma stage III and IV 45 I/II Standard (5–7 days) MCM + PGE2 + TNFα [45]
Melanoma stage III and IV 15 I/II Standard TriMix-mRNA [46]
Melanoma stage III and IV 28 I/II Standard TLR-agonists from conventional vaccines [47]
Uveal melanoma 23 I/II Standard ns [48]
MelanA, MAGE-A3, gp100, and tyrosinase mRNA Melanoma m 12 I Standard (5 days) MCMM [49]
hTERT, survivin, and p53 mRNA Advanced melanoma 22 I Standard ns [50]
MAGE-A3, survivin, BCMA mRNA Multiple myeloma stage II/III 12 I Standard MCMM [51]
MUC1 and survivin mRNA Renal cell carcinoma 28 I/II Standard (4 days) TNFα [52]
CEA mRNA Pancreatic cancer 3 ns Standard No [53]
CEA expressing malignancies 37 I/II Standard No [54]
Colorectal cancer m 5 I/II Standard MCMM [55]
PSA mRNA Prostate cancer m 13 I Standard No [56]
hTERT mRNA, +/− LAMP Prostate cancer m 20 I Standard MCMM [57]
AML 21 II ns ns [58]
PSA, PAP, survivin, and hTERT mRNA Castration-resistant prostate ca 21 II Standard ns [59]
Folat receptor mRNA Ovarian cancer m 1 0 Standard MCMM [60]
WT1 mRNA AML 10 I/II Standard (6 days) TNFα+ PGE2 [61]
Uterine cancer 6 I/II Standard (6 days) TNFα + IL1ß [62]
Ovarian 2 I/II Standard (6 days) TNFα + IL1ß [63]
WT1 mRNA +/− DC-Lamp AML 20 II Standard (6 days) TNFα+ PGE2 [64]
MUC1 mRNA Pancreatic cancer 42 ns Standard (6 days) TNFα [65]
CMV pp65.LAMP mRNA Glioblastoma 12 I Standard MCMM [66]
HSP70 HCV-related hepatocarcinoma 12 I Standard TNFα [67]
CMV pp65 mRNA Hematopoietic stem cell transplantation 7 ns Standard (6 days clinimacs) TNFα, PGE2 [68]
Glioblastoma 11 I Standard from CD34+ ns [69]
Glioblastoma 9 I Standard MCMM [70]
Gag and Nef mRNA HIV infection 10 I/II Standard (5 days) MCMM [71]
Gag, Vpr, Rev and Nef mRNA HIV infection 10 I/II Standard TNFα + IFNγ+ PGE2 + CD40L mRNA [72]
HIV infection 35 IIB Standard TNFa + IFNγ + PGE2 + CD40L-mRNA [73]
Gag-, Tat-, Rev-, and Nef-DC-Lamp mRNA HIV infection 17 I/IIa Standard (6 days) MCMM [74]
Gag- and Tat-Nef-Rev-DC-Lamp mRNA HIV infection 6 I/II Standard (clinimacs) TNFα + PGE2 [75]

m: metastatic, ca: cancer, aT-RNA: autologous tumor RNA, aTSC-RNA: autologous tumor stem cell RNA, AML: acute myeloid leukemia, MAGE: melanoma-associated antigen, Lamp: lysosome-associated membrane protein, hTERT: human telomerase reverse transcriptase, BCMA: B-cell maturation antigen, MUC1: mucin 1, CEA: carcinoembryonic antigen, PSA: prostate-specific antigen, PAP: prostatic acid phosphatase, WT1: Wilms Tumor 1, CMV: cytomegalovirus, HSP70: heat-shock protein 70, Gag: HIV group-specific antigen, Vpr: HIV viral protein R, Rev: HIV reverse transcriptase, Nef: HIV negative regulatory factor, Tat: HIV trans-activator of transcription, MCM: monocyte-conditioned medium, MCMM = MCM-mimic (TNFα, IL-1, IL-6, PGE2), Standard = Monocytes cultured in GM-CSF and IL-4 (default = 7 days), ns: not specified, * Specified as: “single center pilot clinical trial”.